MedTrace Logo

Preoperative Octreotide Treatment of Acromegaly

NCT00521300 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2014-06-02

No results posted yet for this study

Summary

The purpose of this study is to investigate whether 6 months preoperative treatment with the somatostatin analogue octreotide improves the surgical outcome in patients with acromegaly.

Conditions

Interventions

DRUG

Octreotide

First week: Octreotide 50 micrograms subcutaneously three times daily. Second week: Octreotide 100 micrograms subcutaneously three times daily. From the third week on: Octreotide LAR 20 mg intramuscularly every 28th day for 6 months

PROCEDURE

Direct surgery for acromegaly

Direct transsphenoidal surgery

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • St. Olavs Hospital

    lead OTHER

Principal Investigators

  • Sven M Carlsen, MD, PhD · Department of Endocrinology, St. Olavs Hospital, University Hospital of Trondheim, Trondheim, Norway

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-09-30
Primary Completion
2005-06-30
Completion
2010-05-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00521300 on ClinicalTrials.gov